Atripla: tritherapy in one pill arrives in France



France - Atripla, the first triple therapy in treatment once a day, is marketed in France since May 15 It will be borne and reimbursed by Social Security.

Produced by laboratories Gilead and Bristol-Myers Squibb, the Atripla should allow greater ease of adherence. In the mid-1990s, the treatment against AIDS could include more than twenty tablets a day. According to the laboratory, this drug could meet nearly 30 000 of 120 000 infected in France.

Atripla is already available for patients already on treatment, with a rate of virus detectable in blood for more than three months and without a history of failed treatment with other antiviral drugs. It brings together two drugs, Truvada and Sustiva, with the same amount of molecules.

If it already exists in France associations Drug tritherapy meet these combinations of molecules of the same family. Atripla combines complementary molecules. Its three components inhibit the same enzyme but with different mechanisms. If Atripla should make life easier for patients, its side effects remain the same as those of molecules that compose it.

Already on sale in fifty-nine countries including the United States, Atripla has received approval to market in December 2007 and marketing approval in January. The drug will be reimbursed and paid by the Social Security.

Related Posts by Categories